Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care-Reference-Cited by-同舟云学术

Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care

Published:2020-04-29 Issue:25 Volume:41 Page:2393-2396
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Packer Milton¹²^ORCID

Affiliation:

1. Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA

2. Imperial College, London, UK

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/41/25/2393/33449590/ehaa344.pdf

Reference15 articles.

1. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry;Greene;J Am Coll Cardiol,2018

2. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy;Docherty;Eur Heart J,2020

3. EMPA-REG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial;Fitchett;Eur Heart J,2016

4. Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors;Packer;Eur J Heart Fail,2020

5. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action;Packer;Diabetes Care,2020

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physician perceptions, attitudes, and strategies towards implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice;European Journal of Heart Failure;2024-03-22

2. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy;Heart Failure Reviews;2023-06-14

3. Sequencing of medical therapy in heart failure with a reduced ejection fraction;Heart;2022-11-11

4. (Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into Clinical Care? Translation of the document prepared by the Czech Society of Cardiology);Cor et Vasa;2022-09-01

5. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study;Cardiovascular Diabetology;2022-06-03